China 3T MRI Study

Sponsor
Medtronic Cardiac Rhythm and Heart Failure (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06038123
Collaborator
(none)
64
1
9.8

Study Details

Study Description

Brief Summary

The purpose of the China CIED 3.0T MRI Performance Study is to confirm safety of SureScan CIED in the clinical 3.0T MRI environment when subjects receive MRI scans. ll subjects will have required follow-up visits at baseline, MRI visit, 1-month post-MRI. The MRI scans will occur at the MRI visit. The MRI scan region will be determined by investigator according to the subject's clinical condition.

Condition or Disease Intervention/Treatment Phase
  • Device: China market released 3.0T Magnetic resonance (MR) conditional CIED systems
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
64 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
China CIED 3.0T MRI Performance Study
Anticipated Study Start Date :
Oct 7, 2023
Anticipated Primary Completion Date :
Jul 31, 2024
Anticipated Study Completion Date :
Jul 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Subjects with market released 3.0T conditional CIED systems receive 3.0T MRI scans

Signal arm, To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment

Device: China market released 3.0T Magnetic resonance (MR) conditional CIED systems
To confirm safety and effectiveness of the SureScan CIED System in the clinical MRI environment when subjects receive 3.0T MRI scans without positioning restrictions (MRI scans may occur anywhere on the body)

Outcome Measures

Primary Outcome Measures

  1. The occurrence of an MRI-related event for CIED [The event will be collected within 30 days after MRI visit.]

    The occurrence of any of the following within 30 days after the 3.0T MRI visit will be considered an MRI-related event for CIED: Medical advisor-assessed MRI-related complication within 30 days post-MRI Medical advisor-assessed right ventricular MRI-related loss of capture within 30 days post-MRI Sustained tachyarrhythmia originating during SureScan programming, requiring immediate treatment (defined as ATP, device shock, or external shock) as assessed by a medical advisor.

Secondary Outcome Measures

  1. The changes in atrial and ventricular pacing capture thresholds of APCT from pre-MRI to 1-month post-MRI scan. [The evaluation will be compared from pre-MRI to 1-month post-MRI scan]

    PCTs to be evaluated include: Atrial pacing capture threshold (if applicable)

  2. The changes in atrial and ventricular pacing capture thresholds of VPCT from pre-MRI to 1-month post-MRI scan. [The evaluation will be compared from pre-MRI to 1-month post-MRI scan]

    PCTs to be evaluated include: Ventricular pacing capture threshold (both right and left ventricular lead if applicable)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects who were implanted an SureScan system CIED over 6 weeks at the time of signing ICF.

  • Subjects who are able and willing to undergo elective MRI scanning without sedation.

  • Subjects who were implanted an SureScan system CIED in the pectoral region.

  • Subjects who are geographically stable and available for follow-up at the study site for the length of the study.

  • Subjects who are at least 18 years of age (or older, if required by local law).

Exclusion Criteria:
  • Subjects who require a legally authorized representative to obtain informed consent.

  • Subjects with abandoned or capped leads.

  • Subjects who require an indicated MRI scan, other than those specifically described in the China CIED 3.0T MRI performance study, before the 1-month post-MRI follow-up.

  • Subjects with a non-MRI compatible device (such as neurostimulators) or material implant (e.g., non-MRI compatible sternal wires, neurostimulators, biostimulators, metals or alloys).

  • Subjects with medical conditions that preclude the testing required by the CIP or limit study participation.

  • Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the SureScan study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.

  • Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy test within seven (7) days prior to device implant.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Medtronic Cardiac Rhythm and Heart Failure

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Medtronic Cardiac Rhythm and Heart Failure
ClinicalTrials.gov Identifier:
NCT06038123
Other Study ID Numbers:
  • MDT23009
First Posted:
Sep 14, 2023
Last Update Posted:
Sep 14, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2023